Becker's Behavioral Health: 4 Key Facts Clinicians Need to Know About DEA's 7-OH Scheduling Action

Why it matters

Behavioral health providers, addiction treatment clinicians, and hospital administrators need to understand the DEA's temporary scheduling of concentrated 7-OH — particularly which products are now subject to federal criminal law and what the timeline looks like for full enforcement.

The big picture

The temporary scheduling of concentrated 7-OH represents the most significant federal regulatory action on kratom-related products since the DEA's 2016 scheduling attempt (which was withdrawn after public backlash). This time, the action is narrowly scoped to high-concentration and synthetic derivatives, and comes with explicit support from HHS, FDA, and RFK Jr. Behavioral health systems should anticipate changes in patient product use patterns.

Key findings

• HHS confirmed that 7-OH, mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16 have no accepted medical use and a high potential for abuse
• MP, MGM-15, and MGM-16 are purely synthetic — they do not occur naturally in the kratom plant
• The 7-OH threshold is 0.050% by dry weight in botanical materials, or 0.050%/1.00 mg in processed extracts, concentrates, edibles, and pills
• Once temporary orders take effect, manufacture, distribution, sale, and possession of covered 7-OH substances become subject to federal criminal, civil, and administrative provisions of the Controlled Substances Act
• HHS's OASH opened a 30-day public comment period on the threshold level, with comments due July 31, 2026; after review, the Attorney General may issue a final two-year temporary scheduling order

What they say

"HHS confirmed synthetic 7-OH and the three related substances — mitragynine pseudoindoxyl, MGM-15 and MGM-16 — have no accepted medical use and a high potential for abuse," according to Becker's Behavioral Health reporting on the July 1, 2026 DEA action.

Bottom line

The DEA's temporary scheduling of concentrated 7-OH creates new federal criminal exposure for manufacturers and sellers, while the 30-day public comment period through July 31 offers a narrow window for scientific input on the specified threshold.